---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-014430"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2022-09-15T23:59:59+00:00"
generated_at: "2026-06-23T09:29:40.112730+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Xilio appoints Tomas Heyman to Board of Directors

## Summary
- Tomas Heyman appointed as Class I director effective September 15, 2022.
- He will serve until the 2025 annual meeting or until earlier resignation.
- Appointed to Nominating and Corporate Governance Committee and Audit Committee.
- Compensation follows standard non-employee director arrangements as disclosed in 2022 proxy statement.

## SEC filing metadata
- accession: 0001558370-22-014430
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2022-09-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837022014430/0001558370-22-014430-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837022014430/xlo-20220915x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-014430
- JSON: https://secwatch.observer/filing/0001558370-22-014430.json
- Plain text: https://secwatch.observer/filing/0001558370-22-014430.txt

## Key facts
- Executive change
  Tomas Heyman was appointed as Class I director at Xilio Therapeutics, Inc..
  - Action: appointed
  - Role: Class I director
  source text: Effective September 15, 2022, the Board of Directors (the “Board”) of Xilio Therapeutics, Inc. (the “Company”), on the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Tomas Heyman to the Board as a Class I director of the Company, to serve in such capacity until the Company’s 2025 annual meeting of stockholders or until his earlier resignation, death, or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837022014430/0001558370-22-014430-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.